Explore / Peer-reviewed article
Peer-reviewed article

Psychedelic Medicine Exceptionalism.

Cohen IGiD, Marks MiD

The American journal of bioethics : AJOBJan 13, 202516 citationsDOI: 10.1080/15265161.2025.2434398

Abstract

Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical interventions. In other words, identical standards should apply. This article analyzes whether psychedelic medicines warrant special consideration from a regulatory and ethical perspective.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinMDMA

Keywords

Informed consentpsychotherapyFdaPsychedelics

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.